Sign in →

Test ID: PGXFP Focused Pharmacogenomics Panel

Specimen Required

Submit only 1 of the following specimens:


Specimen Type: Whole blood

Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send specimen in original tube.

Specimen Stability Information: Ambient (preferred)/Refrigerated


Specimen Type: Saliva

Patient Preparation: Patient should not eat, drink smoke, or chew gum 30 minutes prior to collection.

Supplies: DNA Saliva Collection Kit (T786)

Container/Tube: Saliva Swab Collection Kit (T786: fees apply)

Specimen Volume: 1 swab

Collection Instructions: Collect and send specimen per kit instructions.

Specimen Stability Information: Ambient

Additional Information: Due to lower concentration of DNA yielded from saliva, testing cannot proceed to reflex testing for 2D6 sequencing and will stop after initial testing is complete.


Specimen Type: DNA

Container/Tube: 2 mL screw top tube

Specimen Volume: 100 mcL (microliters)

Collection Instructions:

1. The preferred volume is 100 mcL at a concentration of 50 ng/mcL.

2. Include concentration and volume on tube.

Specimen Stability Information: Frozen (preferred)/Ambient/Refrigerated


1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (T576) is available in Special Instructions.

2. If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Neurology Specialty Testing Client Test Request (T732) (

Pharmacogenomics Test Request Form (T797) (

Useful For

Preemptive or reactive genotyping of patients for pharmacogenomic purposes


Providing an assessment for genes with strong drug-gene associations

Testing Algorithm

If a specimen requires follow-up for CYP2D6, then reflex testing will be performed as appropriate at an additional charge.


See CYP2D6 Comprehensive Cascade Testing Algorithm in Special Instructions.

Method Name

Real Time Polymerase Chain Reaction (RT-PCR) with Allelic Discrimination Analysis with Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis when appropriate

Reporting Name

Focused Pharmacogenomics Panel

Specimen Type


Specimen Minimum Volume

Blood: 1 mL
Saliva: 1 swab

Specimen Stability Information

Specimen Type Temperature Time
Varies Varies

Clinical Information

This panel provides a comprehensive analysis for multiple genes with strong drug phenotype associations. Each sample is tested for specific variations with known functional impact. Pharmacogenomic data for the following specific variants are reviewed and reported (if present):

CYP1A2 *1F, *1K, *6, and *7

CYP2C9 *2, *3, *4, *5, *6, *8, *9, *11, *12, *13, *14, *15, *16, *17, *18, *25, *26, *28, *30, *33, and *35

CYP2C19 *2, *3, *4, *5, *6, *7, *8, *9, *10, *17, and *35

CYP2D6 *2, *2A, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B,*15, *17, *29, *35, *36, *41, *68, and CYP2D6 gene duplication; additional CYP2D6 variants may be detected through the reflex testing process

CYP3A4 *8, *11, *12, *13, *16, *17, *18, *22, and *26

CYP3A5 *3, *5, *6, *7, *8, and *9

CYP4F2 *3


SLCO1B1 rs4149056 variant found in the *5, *15 and *17 alleles, and rs4149015 found in the *17 and *21 alleles

VKORC1 c. -1639G>A, c.85G->T, c.106G->T, c.121G->T, c.134T->C, c.172A->G, c.196G->A, c.358C->T, and c.383T->G


Based on the results of each assay, a genotype is assigned and a phenotype is predicted for each gene. Assessment of multiple genes may assist the ordering clinician with personalized drug recommendations, avoidance of adverse drug reactions, and optimization of drug treatment.

Reference Values

An interpretive report will be provided.


An interpretive report will be provided that focuses on only drugs and genes with published pharmacogenomic practice guidance by the Clinical Pharmacogenetics Implementation Consortium, other professional organizations or where strong FDA guidance has been issued in drug labels.


For additional information regarding pharmacogenomic genes and their associated drugs, see Pharmacogenomic Associations Tables in Special Instructions. This resource also includes information regarding enzyme inhibitors and inducers, as well as potential alternate drug choices.

Clinical Reference

1. Ji Y, Skierka JM, Blommel JH, et al: Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn 2016 May;18(3):438-445

2. Samwald M, Xu H, Blagec K, et al: Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. PLoS One 2016 Oct 20;11(10):e0164972

3. Clinical Pharmacogenetic Implementation Committee Gene-Drug Table. Accessed 5/4/2017. Available at

4. Pharmacogenomics Knowledgebase (PharmGKB). Accessed 5/4/2017. Available at

Day(s) and Time(s) Performed

Monday through Friday; 8 a.m.

Analytic Time

3 days (not reported Saturday or Sunday)

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information




81479-Unlisted molecular pathology procedure (if appropriate)


81479-Unlisted molecular pathology procedure (if appropriate)


81479-Unlisted molecular pathology procedure (if appropriate)


81479-Unlisted molecular pathology procedure (if appropriate)


81479-Unlisted molecular pathology procedure (if appropriate)


81479-Unlisted molecular pathology procedure (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PGXFP Focused Pharmacogenomics Panel 82118-1


Result ID Test Result Name Result LOINC Value
BA0902 Medications 52418-1
BA0903 Amitriptyline In Process
BA0904 Aripiprazole In Process
BA0905 Atomoxetine In Process
BA0906 Atorvastatin In Process
BA0914 Brexpiprazole In Process
BA0907 Carvedilol In Process
BA0915 Carisoprodol In Process
BA0908 Celecoxib In Process
BA0909 Citalopram In Process
BA0152 Clobazam In Process
BA0910 Clomipramine In Process
BA0911 Clopidogrel In Process
BA0912 Codeine In Process
BA0913 Desipramine In Process
BA0263 Dexlansoprazole In Process
BA0235 Dextromethorphan In Process
BA0916 Diclofenac In Process
BA0917 Doxepin In Process
BA0233 Eliglustat In Process
BA0918 Escitalopram In Process
BA0919 Esomeprazole In Process
BA0244 Flecainide In Process
BA0920 Fluoxetine In Process
BA0921 Fluvoxamine In Process
BA0922 Fosphenytoin In Process
BA0245 Haloperidol In Process
BA1630 Iloperidone In Process
BA0923 Imipramine In Process
BA0924 Lansoprazole In Process
BA0925 Metoprolol In Process
BA0926 Nortriptyline In Process
BA0927 Omeprazole In Process
BA0928 Ondansetron In Process
BA0929 Oxycodone In Process
BA0930 Pantoprazole In Process
BA0931 Paroxetine In Process
BA1631 Perphenazine In Process
BA0932 Phenytoin In Process
BA1632 Pimozide In Process
BA0933 Pravastatin In Process
BA1633 Propafenone In Process
BA1634 Risperidone In Process
BA0934 Rosuvastatin In Process
BA0935 Sertraline In Process
BA0936 Simvastatin In Process
BA0937 Sirolimus In Process
BA0938 Tacrolimus In Process
BA0939 Tamoxifen In Process
BA0940 Tamsulosin In Process
BA1635 Tetrabenazine In Process
BA1636 Thioridazine In Process
BA0941 Tramadol In Process
BA0942 Trimipramine In Process
BA0943 Tropisetron In Process
BA0944 Venlafaxine In Process
BA0945 Voriconazole In Process
BA0946 Warfarin In Process
BA0947 Other Medications In Process
BA0261 CYP1A2 Genotype In Process
BA0262 CYP1A2 Phenotype In Process
BA0258 CYP2C19 Genotype In Process
BA0259 CYP2C19 Phenotype 79714-2
BA0264 CYP2C9 Genotype In Process
BA0265 CYP2C9 Phenotype 79716-7
BA0255 CYP2D6 Genotype In Process
BA0256 CYP2D6 Phenotype 79715-9
BA0252 CYP3A4 Genotype 81139-8
BA0253 CYP3A4 Phenotype 53040-2
BA0249 CYP3A5 Genotype In Process
BA0250 CYP3A5 Phenotype 79717-5
BA0246 SLCO1B1 Genotype In Process
BA0247 SLCO1B1 Phenotype 79722-5
BA0228 WARF CYP2C9 Genotype In Process
BA0229 WARF VKORC1 Genotype In Process
BA0150 Additional VKORC1 Variants In Process
BA0230 CYP4F2 *3 Genotype In Process
BA0231 rs12777823 Genotype In Process
BA0151 Interpretation In Process
BA0267 Additional Information 48767-8
BA0268 Method 49549-9
BA0269 Disclaimer 62364-5
BA0270 Reviewed by In Process
Mayo Medical Laboratories | Genetics and Pharmacogenomics Catalog Additional Information: